Le Lézard

News by subject: TRI

1 2 3 4 5 6 7 8 9 10

30 november 2022

22:00
CNS Pharmaceuticals, Inc. ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of a public...

19:21
The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer's will require drugs that do more than clear amyloid plaques. While...

18:00
Eli Lilly and Company has announced that donanemab met all primary and secondary endpoints for the 6-month primary outcome analysis in the Phase 3...

14:54
Freespira, Inc., developer of the only FDA-cleared treatment for symptoms of panic disorder and post-traumatic stress disorder (PTSD), published a study showing the effectiveness of its at-home treatment to help patients with these mental health...

14:50
Nutraceuticals Innovator TruZen® Health has announced the results of a first ever human-based clinical trial, proving its proprietary TruZen® CBD formula with patented VESIsorb® Technology achieves 360% greater...

14:45
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease...

14:00
- A team of US and European researchers have released new findings in Science Advances showing how the SARS-CoV-2 Spike (S)-protein interacts with human Estrogen Receptor Alpha (ER?) in lung tissue - Data released as pre-print on bioRxiv reveals the...

12:00
USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS),...

11:07
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitorsElacestrant side effects were manageable and...

09:00
Centinel Spine®, LLC, ("the Company") a leading global medical device company addressing cervical and lumbar spinal disease...

09:00
Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal antibody that selectively targets only the active...

08:39
A recent study showed that wearing special green-tinted eyeglasses reduces pain in patients with fibromyalgia and others who experience chronic pain.  This may help decrease the need for opioids to manage severe pain in the three million Americans...

08:12
Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immuno-oncology (IO) treatments, announced...

08:05
Regeneron Pharmaceuticals, Inc.  today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct...

08:00
Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, will present clinical data on lead therapeutic candidate, PT-112, in combination with avelumab, and its immunogenic cell death...

08:00
IceCure Medical Ltd. ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced that...

07:39
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023 -- Clinical efficacy observed in patients who have completed 12-week...

07:30
Filament Health Corp. (NEO: FH) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced that it has been issued two new patents for the extraction and standardization of natural psilocybin and...

07:00
The results of a clinical trial using software from XRHealth, developer and operator of virtual treatment rooms in the metaverse, published in MDPI highlights that the combination of virtual reality and artificial intelligence reduces hot flashes and...

07:00
Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of...

07:00
A change in the DNA code (mutation) of a gene that plays a key role in the brain's immune defenses may prevent related cells from clearing away protein-filled clumps, a new study in mice shows. The buildup of such clumps, also called plaque, sets off...

05:00
A minimally invasive treatment for carpal tunnel syndrome provides complete and long-term relief to patients without the use of corticosteroids, according to research being presented today at the annual meeting of the Radiological Society of North...

03:30
ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat...

02:00
Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that it enrolled the first participant in a phase I first in-human clinical trial of Avacc 10®, the company's SARS-CoV-2...


29 november 2022

22:34
BioArctic AB's (publ) (Stockholm: BIOA B) partner Eisai announced today that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (A?)...

22:15
BioArctic AB's (publ) partner Eisai announced today that the results from the large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (A?) protofibril antibody for...

22:08
The Alzheimer's Association welcomes and is further encouraged by the full Phase 3 data presented by Eisai and Biogen from the CLARITY AD global Phase 3 clinical trial of lecanemab. The data presented today and published in the New England Journal of...

20:16
Based on study results presented today at the 15th Clinical Trials on Alzheimer's Disease (CTAD) conference and published in The New England Journal of Medicine, amyloid-clearing drug lecanemab?poised for FDA approval early next year?will be a...

19:50
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational...

19:50
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational...

19:00
Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial in the United States comparing HANSIZHUANG (serplulimab), an innovative anti-PD-1 monoclonal antibody (mAb)...

14:36
Cordio Medical, a market-leading medical speech processing platform, shared key findings in the HearOtmCommunity Study: Remote Speech Analysis of Hospitalized Patients with Acute Decompensated Heart Failure that assessed remote speech analysis...

11:30
AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer's disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th...

11:00
Candesant Biomedical ("Candesant"), a clinical-stage company focused on the development of non-invasive treatments for primary hyperhidrosis (excessive sweating), today announced the publication of a pilot study showing that its investigational "TAT"...

10:50
Allied Market Research recently published a report, titled, "Cri-du-chat Syndrome Treatment Market by Treatment (Physiotherapy, Speech therapy, Occupational therapy), by End User (Hospitals and specialty clinics, Others): Global Opportunity Analysis...

10:49
TrialSpark announced today the formation of Libertas Bio following the acquisition of a majority position in a portfolio of immunodermatology assets from Asana BioSciences. The Libertas Bio pipeline now includes global rights to gusacitinib, an oral...

10:37
Slope, provider of the first eClinical Supply Chain Management (eCSCM) platform, announced general availability of its interactive Study Dashboard for Sponsors to address challenges coordinating and overseeing clinical supply chain management for one...

10:00
One in three adults with epilepsy experience depressive symptoms. Medications and therapy have been shown to be effective in reducing depressive symptoms but people with epilepsy do not always have timely access to these treatment options. To respond...

10:00
A first-of-its-kind digital therapeutics research study may offer new hope for patients with a rare lung disease and are having difficulty with anxiety. Vicore Pharma recently launched the study across the U.S....

10:00
UroMems, a global company developing breakthrough, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it has successfully completed the first-in-human implant of the UroActivetm System, the first smart automated...

10:00
Vaica Medical, a leading provider of medication adherence and remote patient management technology, announced it was chosen by Children's Hospital of Michigan, Pediatric Heart Transplant Center, as technology partner.  ...

09:25
Medivir AB , a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will present at the Erik Penser Bank Healthcare Day on December 1, 2022. CEO Jens...

09:00
Quotient Sciences, a global drug development and manufacturing accelerator, today announced a partnership with Emplicure, a Swedish pharmaceutical company focused on chronic pain and abuse-deterrent formulations. The partnership will see Quotient...

09:00
WCG, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today launched a new Electronic Seizure Diary (eDiary), which is used to help patients with seizure disorders and their caregivers...

08:58
We are advised by AmyriAD Therapeutics that journalists and other readers should disregard the news release, AmyriAD to Present Clinical and Preclinical Data at the 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference, issued 29-Nov-2022...

08:48
Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the World Health Organization (WHO) has issued an updated Emergency Use Listing (EUL)...

08:40
Oramed Pharmaceuticals Inc. (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that Diabetes, Obesity, and Metabolism, has published an original article titled: "Oral...

08:30
AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer's disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th...

08:00
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to proceed with clinical study of [18F]FAPI-74, its lead fluorine-18 labelled Fibroblast Activation...

08:00
Sherlock Biosciences, a company engineering biology to bring next-generation diagnostics to the point of need, today announced that it has received additional funding from the Bill & Melinda Gates Foundation to advance its rapid, instrument-free...

1 2 3 4 5 6 7 8 9 10